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Abstract Introduction: ORM-12741 is a novel selective antagonist of alpha-2C adrenoceptors. This trial eval-
uated the safety and efficacy of ORM-12741 in patients with Alzheimer’s disease (AD).
Methods: A randomized, double-blind, placebo-controlled, exploratory phase 2a trial was conduct-
ed in 100 subjects with AD and neuropsychiatric symptoms. Participants were randomized to receive
one of two flexible doses of ORM-12741 (30–60 mg or 100–200 mg) or placebo b.i.d. for 12 weeks in
addition to standard therapy with cholinesterase inhibitors. Efficacy was assessed primarily with the
Cognitive Drug Research (CDR) computerized assessment system and secondarily with the Neuro-
psychiatric Inventory (NPI).
Results: A statistically significant treatment effect was seen in one of the four primary CDR system
end points, Quality of Episodic Memory (P5 .030; not adjusted for multiple comparisons), favoring
ORM-12741 over placebo. NPI caregiver distress scores also favored ORM-12741 (P5 .034). ORM-
12741 was well tolerated.
Discussion: This is the first clinical trial providing evidence on an acceptable safety profile for ORM-
12741 in patients with AD and neuropsychiatric symptoms. In addition, the trial provided hints of
potential therapeutic benefit, primarily on episodic memory, in this patient population.
 2016 Orion Pharma. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Keywords: Alzheimer’s disease; Cognition; Memory; Alpha-2C adrenoceptor antagonist; ORM-12741; Randomized trials;
Behavioral and psychological symptoms of dementia; Neuropsychiatric symptoms
1. Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia and a major cause of morbidity and mortality.
Current approved drug treatments for AD include cholines-
terase inhibitors (donepezil, rivastigmine, galantamine)
and the N-methyl-D-aspartate receptor antagonist meman-
tine. The effects of these medications are symptomatic and
efficacy is considered to be modest [1]. Many patients have
neuropsychiatric symptoms (NPSs) in the course of their
cognitive decline, and there are no approved treatments
that can be recommended for long-term use for these
important comorbid conditions. There is an urgent need
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for better treatment alternatives targeting cognitive impair-
ment as well as NPS in patients with AD [1–3].
According to a recent analysis of the AD drug develop-
ment pipeline, there were 24 compounds in phase 3 and 45
compounds in phase 2 clinical trials [4]. Most of the mole-
cules that are being developed for AD are aiming for disease
modification. However, as it is unlikely that any of the com-
pounds now in clinical development will be able to totally
prevent the development of dementia in all patients, symp-
tomatic therapies will still be needed for a long time.
Alpha-2 adrenoceptors (ARs) are distributed throughout
the central nervous system and peripheral tissues andmediate
many physiological and pharmacological actions of endoge-
nous catecholamines. Alpha-2 ARs consist of three distinct
subtypes, alpha-2A, alpha-2B, and alpha-2C, each encoded
by its own gene. Current knowledge suggests that the major-
ity of classical alpha-2 adrenergic agonist actions (such as
sedation, analgesia, and bradycardia) are mediated by the
alpha-2AAR,whereas the other subtypes act as “fine-tuners”
of related functions and may sometimes mediate opposite
functional effects [5]. The highest densities of alpha-2C
ARs are found in the ventral and dorsal striatum and in the
hippocampus. Alpha-2C ARs may play an important role in
the modulation of dopamine and serotonin neurotransmis-
sion in the brain [6]. These effects seem to be especially
prominent under stressful conditions [6]. At the behavioral
level, alpha-2C ARs modulate the performance of experi-
mental animals in tests predicting antidepressant and antipsy-
chotic efficacy as well as learning and memory functions [6].
Consistent with this, specific and subtype-selective alpha-2C
AR antagonists have shown positive effects in various
nonclinical models predicting efficacy on cognition as well
as symptoms of schizophrenia and depression [7,8].
ORM-12741 is a potent, specific, and subtype-selective
alpha-2C AR antagonist that was well tolerated in phase I
studies (Orion Pharma, unpublished results; for study design in-
formation, seeNCT00693316, NCT00792493, NCT00817544,
NCT00818740,NCT00831077,NCT01068028). Its pharmaco-
kinetic properties make ORM-12741 suitable for oral use, and
the compound has demonstrated concentration-dependent
alpha-2C AR occupancy in vivo in the human brain (Lovro
et al., unpublished results; see NCT00829907), as investigated
with positron emission tomography (PET) imaging [9–11].
The primary objectives of this study were to evaluate the
safety and tolerability of ORM-12741 and the efficacy of
ORM-12741 on cognitive performance in patients with
AD receiving standard cholinesterase inhibitor therapy.
The secondary objectives of the study were to evaluate the
efficacy of ORM-12741 on NPS.
2. Methods
2.1. Participants
Male and female subjects aged 55–90 years with a diagnosis
of probable AD according to National Institute of Neurological
and Communicative Disorders and Stroke-Alzheimer’s Dis-
ease and Related Disorders Association (NINCDS-ADRDA)
[12] and Dementia of the Alzheimer’s Type according to Diag-
nostic and Statistical Manual of Mental Disorders, 4th edition
Text Revision (DSM-IV-TR) [13] criteria were recruited. All
study subjects were required to have a history of progressive
cognitive deterioration, brain imaging consistent with AD, a
Mini–Mental State Examination (MMSE) score of 12–21, a
10-item Neuropsychiatric Inventory (NPI) [14] total score
15 and stable usage of cholinesterase inhibitors at standard
doses for at least 2 months. Use of memantine and/or serotonin
reuptake inhibitors was also allowed, if on stable doses. All
study subjects were required to have a committed caregiver
who was able and willing to assist them with medications
and provide study subject information.
Key exclusion criteria were any type of dementia other
than AD, modified Hachinski ischemia score of.4, a history
or evidence of any other significant disease that could impair
cognition, and residence in a skilled nursing facility. Subjects
who were not able to complete the CDR system tests (www.
bracketglobal.com) after a training session were excluded.
Subjects who had used antipsychotics or anticholinergics
within the previous 2 months were also excluded.
2.2. Study design
This double-blind, placebo-controlled, parallel-group
exploratory clinical phase 2a trial was conducted between
April 2011 and September 2012 at 18 clinical sites in
Finland, Poland, Romania, and Spain.
Study participants were equally randomized into three par-
allel groups to receive one of two flexible dose levels of
ORM-12741 (30–60 mg or 100–200 mg) or placebo orally
twice a day for 12 weeks in addition to their stable cholines-
terase inhibitor therapy (donepezil, rivastigmine, or galant-
amine) through a central interactive Web-response system
according to a computer-generated, randomized allocation
schedule. Randomization was stratified according to the
MMSE score (12–16 vs. 17–21). The low-dose group
received 30 mg for the first week and 60 mg in subsequent
weeks; the high-dose group received 100 mg for the first
week and 200 mg in subsequent weeks. The investigators
were permitted to reduce the dose to the starting dose if the
higher dose was poorly tolerated. Blinding was accomplished
with the use of placebo capsules that were identical in appear-
ance to the ORM-12741 capsules. Dose increases and reduc-
tions were similarly performed in the placebo group.
2.3. Outcomes
2.3.1. Efficacy
The nine core tests of the CDR system for patients with de-
mentia were used to assess efficacy [15]. These tests comprised
simple reaction time, choice reaction time, digit vigilance,
numeric and spatial working memory, immediate and delayed
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word recall, andword and picture recognition. The four prespe-
cified primary efficacy outcomes for cognitive performance
were changes from baseline to week 12 in the CDR System
standard composite domain factor scores [16]: Quality of
Episodic Memory, Quality of Working Memory, Power of
Attention and Speed of Memory Retrieval, as also used previ-
ously in many dementia trials [17–19]. Furthermore, a
prespecified composite score for Continuity of Attention was
calculated and additionally, a Quality of Memory composite
score, combining the accuracy scores from all working and
episodic memory tasks, was calculated after unblinding the
treatment assignment to further characterize the effects of
ORM-12741 [16]. After two training sessions at the screening
visit, each subject completed the CDR system tasks at baseline
and at the weeks 1, 2, 4, 8, and 12 visits about 1 hour after the
morning dose, near the anticipated maximum plasma concen-
tration of ORM-12741.
Secondary efficacy for NPS was assessed by the NPI rat-
ing scale [14], including the 10-item NPI total score and NPI
caregiver distress score. The NPI was assessed at screening,
at baseline and at weeks 4 and 12.
Other exploratory efficacy outcome measures were the
Controlled Oral Word Association Test (COWAT) [20],
Category Fluency Test (CFT) [21], Cornell Scale for Depres-
sion in Dementia (CSDD) [22], Clinical Global Impression
of Change (CGI-C) [23], and self-rated Cognitive Failures
Questionnaire (CFQ) [24].
2.3.2. Pharmacokinetics
Pharmacokinetic blood samples were collected at base-
line and before the morning dose of study medication at
weeks 1, 2, 4, 8, and 12. Plasma concentrations of ORM-
12741 and cholinesterase inhibitors were determined using
validated methods based on liquid chromatography–tandem
mass spectrometry.
2.3.3. Safety
Safety was assessed at each visit by adverse events, blood
pressure, heart rate, 12-lead ECG, and laboratory tests.
Blood pressure and heart rate were recorded in supine posi-
tion before and 1 and 2 hours after the morning dose, fol-
lowed by orthostatic test measurements after 3 minutes of
standing. Physical examinations were performed during
screening, at baseline and at weeks 4 and 12.
2.4. Statistical analysis
The sample size for this exploratory phase 2a trial was
based on practical consideration, and no formal power calcu-
lations were performed. The primary efficacy assessment
was performed on themodified intention-to-treat population,
defined as subjects who received at least one dose of study
medication and had completed baseline assessments and at
least one post-baseline CDR system test session.
All statistical tests were two sided with a 0.05 level of sig-
nificance. No adjustments were made for multiple compari-
sons. A mixed-effects model for repeated measurements
with 95% confidence intervals (CIs) was used to compare
changes in the continuous primary and secondary outcomes.
The models included treatment, time point and treatment by
time point interaction as fixed effects, study site as a random
effect, and baseline value of the outcome variable in question
as a covariate. Least squares means (LS means) and standard
error (SE) of means were calculated for effects of treatment
and treatment by time point interaction. In addition, effect
sizes were calculated using Cohen’s dmethod [25]. The resid-
ual error termwas used, and the square root of this was used as
the denominator, and the differences in LS means between
placebo and active conditions were used as the numerator.
The categorical outcome measure, CGI-C, was compared
with the generalized linear model and 95% CIs. One-way
analysis of variance, the c2 test and Fisher exact test were
Table 1
Baseline characteristics of the study participants
Baseline characteristic Placebo (N 5 34) ORM-12741, 30–60 mg (N 5 33) ORM-12741, 100–200 mg (N 5 33) Total (N 5 100)
Sex, n (%)
Female 17 (50.0) 19 (57.6) 23 (69.7) 59 (59.0)
Male 17 (50.0) 14 (42.4) 10 (30.3) 41 (41.0)
Age, years 72.3 (8.5) 71.8 (8.2) 71.8 (6.8) 72.0 (7.8)
MMSE score 18.1 (2.7) 18.6 (2.4) 19.0 (2.5) 18.5 (2.6)
NPI total score 22.7 (11.7) 21.2 (7.7) 19.0 (7.6) 21.0 (9.3)
NPI caregiver distress score 10.4 (6.8) 10.6 (5.4) 9.8 (4.3) 10.2 (5.6)
Age at diagnosis of AD, years 71.2 (8.3) 70.6 (7.8) 70.5 (6.8) 70.8 (7.6)
Duration of AD, years 1.6 (1.4) 1.7 (1.6) 1.9 (1.4) 1.7 (1.5)
Use of cholinesterase inhibitors and memantine, n (%)
Donepezil 23 (67.6) 20 (60.6) 22 (66.7) 65 (65.0)
Galantamine 2 (5.9) 2 (6.1) 1 (3.0) 5 (5.0)
Rivastigmine 9 (26.5) 11 (33.3) 10 (30.3) 30 (30.0)
Memantine 5 (14.7) 3 (9.1) 3 (9.1) 11 (11.0)
Duration of cholinesterase inhibitor and memantine therapies, years
Cholinesterase inhibitors 1.5 (1.4) 1.6 (1.5) 1.6 (1.4) 1.6 (1.5)
Memantine 1.3 (0.7) 1.6 (0.8) 0.9 (0.6) 1.3 (0.7)
Abbreviations: AD, Alzheimer disease; MMSE, Mini–Mental State Examination; NPI, Neuropsychiatric Inventory; SD, standard deviation.
NOTE. Values are mean (SD) unless otherwise stated. None of the comparisons between the treatment groups was statistically significant.
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used to evaluate possible differences between the treatment
groups in the subjects’ baseline characteristics (Table 1).
2.5. Protocol approvals, consents, and registrations
Permission to conduct the study was received from each
national regulatory agency before commencement. The
study protocol and amendments were approved by an ethics
committee at each clinical site. Written informed consent
was obtained from all study subjects and their caregivers.
This study was conducted in compliance with the Declara-
tion of Helsinki and International Conference on Harmoni-
sation Good Clinical Practice Guidelines and is registered
on Clinicaltrials.gov (NCT01324518).
3. Results
3.1. Participants
Of the 132 subjects screened for the study, 100 subjects
were randomized and 91 subjects completed the study. All ran-
domized subjects were included in the efficacy and safety an-
alyses. Fig. 1 summarizes subject enrollment and participation.
Baseline characteristics were similar in the three treatment
groups (Table 1). The mean subject age was 72 years (range
55–90); 59% were female. Ninety-nine subjects (99%) were
Caucasian and one subject was Hispanic. All subjects used
cholinesterase inhibitors and 11 subjects (11%) used meman-
tine for the treatment of AD. Antidepressants were used by 12
(36%), 10 (30%), and 10 (29%) subjects in the low-dose,
high-dose, and placebo groups, respectively.
Dose adjustments were allowed for tolerability. Study
treatment dosage was reduced for 8 subjects (8%): for two
subjects from ORM-12741 60–30 mg, for three subjects
from ORM-12741 200–100 mg, and for three subjects the
placebo dose was reduced to half.
3.2. Cognitive performance
Compared to placebo, statistically significant treatment
effects favoring active treatment were observed on Quality
of Episodic Memory composite scores over 12 weeks of
treatment, with no clear differences between the two dose
levels of ORM-12741 (Fig. 2). The Quality of Episodic
Memory composite scores decreased from baseline to
week 12 by a mean (SD) of 232.4 (50.6) points in the pla-
cebo group, increased by 4.6 (51.5) points in the low-dose
Fig. 1. Disposition of subjects.
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group and increased by 5.2 (42.5) points in the high-dose
group. The overall treatment effect for the Quality of
Episodic Memory composite score was statistically signifi-
cant (P 5 .030). In pairwise comparisons, both dose levels
of ORM-12741 showed statistically significant efficacy
over placebo. The estimated treatment difference was 16.5
points (95% CI 0.28 to 32.63, P 5 .046) for the low dose
versus placebo and 20.6 points (95% CI 4.57 to 36.7,
P5 .012) for the high dose versus placebo (Table 2). The Co-
hen’s d effect size was 1.09 for the low dose versus placebo
and 1.02 for the high dose versus placebo at 12 weeks.
The overall treatment effect was not statistically signifi-
cant (P5 .193) for the Quality ofWorkingMemory compos-
ite score. The low dose showed an overall trend for
improvingWorking Memory over the 12 weeks of treatment
(Fig. 2). The estimated treatment difference was 0.16 points
(95% CI 20.02 to 0.33, P 5 .079) for the low dose versus
placebo and 0.11 points (95% CI 20.06 to 0.28, P 5 .219)
for the high dose versus placebo (Table 2). The effect size
was 0.88 for the low dose versus placebo and 0.55 for the
high dose versus placebo at 12 weeks.
The most marked difference between ORM-12741 and
placebo was seen in the post hoc–calculated Quality of Mem-
ory composite score that combines all of the accuracy mea-
sures from the six tests included in the Quality of Episodic
and Working Memory composite scores. The overall treat-
ment effect was statistically significant (P 5 .013) over the
12 weeks of treatment, with subjects in both ORM-12741
dose groups improving on Quality of Memory and subjects
on placebo showing a steady decline. The estimated treatment
difference was 37.4 points (95% CI 10.9–63.9, P 5 .006) for
the low dose versus placebo and 31.1 points (95% CI 5.19 to
57.1, P 5 .019) for the high dose versus placebo (Table 2).
The effect size was 1.54 for the low dose versus placebo
and 1.12 for the high dose versus placebo at 12 weeks.
No statistically significant treatment effect was detected
in the other composite cognitive domain scores of Speed
of Memory, Power of Attention, or Continuity of Attention
(Table 2).
3.3. Neuropsychiatric symptoms
A statistically significant (P 5 .034) treatment effect in
favor of ORM-12741 was observed for the NPI caregiver
distress score. The NPI caregiver distress score decreased
by a mean (SD) of 22.4 (4.8) points in the low-dose group
and by22.1 (3.4) points in the high-dose group. No change
was observed (mean 0.4, SD 4.9) in the placebo group
(Fig. 3). The estimated treatment difference was 22.13
points (95% CI 23.92 to 20.35, P 5 .020) for the
low dose versus placebo and 21.94 points (95% CI 23.7
to 20.18, P 5 .031) for the high dose versus placebo. The
effect size was 21.22 for the low dose versus placebo
and 20.96 for the high dose versus placebo at 12 weeks.
No statistically significant treatment effects were seen in
the NPI total score (Fig. 3). However, a numerical trend for
improvement was seen in the low-dose group compared to
placebo.
3.4. Additional efficacy end points
No statistically significant treatment effects were de-
tected between active treatment and placebo for COWAT,
CFT, CSDD, CFQ (Supplementary Table 1), or the CGI-C
(Supplementary Table 2).
Fig. 2. Quality of Episodic Memory, Quality of Working Memory, and
Quality of Memory CDR composite scores. Data are presented as LS means
(SE) for changes from baseline. A positive change from baseline indicates
improvement. *P , .05, **P , .01, ***P , .001 for difference versus pla-
cebo at time point. Abbreviations: CDR, Cognitive Drug Research; LS
means, least squares means; SE, standard error.
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3.5. Pharmacokinetics
ORM-12741 did not accumulate during the 12 weeks
of treatment. Steady-state concentrations were reached
after 2 weeks of treatment. The mean (SD) plasma
trough concentration was 18.4 (13.9) ng/mL for the
low dose and 61.0 (45.9) ng/mL for the high dose at
week 12. ORM-12741 did not have significant effects
on the concentrations of cholinesterase inhibitors
(data not shown).
3.6. Safety
There were no notable differences in the frequency of
adverse events among the three groups (Table 3). One sub-
ject experienced cholestasis with asymptomatic high liver
enzyme values after 4 weeks of high-dose treatment. This
was reported as a serious adverse event and the subject dis-
continued the trial. All adverse events are presented by sys-
tem organ class and preferred term in Supplementary
Table 3.
There were no clinically meaningful changes from base-
line in the mean safety laboratory values. Standing heart
rate values in the high-dose group were slightly above than
those in the placebo group. However, no statistically signifi-
cant treatment effect was observed (the estimated LS mean
for difference was at most 14.3 bpm in the high-dose group
compared to the placebo group 1 hour after dosing at week 1).
No clinicallymeaningful changes were seen in blood pressure
and 12-lead ECG variables, including the QTc interval.
4. Discussion
This phase 2a proof-of-concept clinical trial was conduct-
ed to evaluate the safety and efficacy of two dose levels of
ORM-12741 (30–60 mg and 100–200 mg) compared to pla-
cebo for 12 weeks in patients with AD and NPS, all receiving
standard cholinesterase inhibitor therapy. Statistically sig-
nificant positive treatment effects were noted for both
ORM-12741 dose levels compared to placebo on the prespe-
cified efficacy analyses for the Quality of Episodic Memory
composite score of the CDR cognitive battery. This was sup-
ported by a consistently positive trend for the Quality of
Working Memory composite score, which consist of sub-
scores assessed independently from the Quality of Episodic
Memory composite score. Positive treatment effects were
noted also for the post hoc–calculated Quality of Memory
composite score that combines subscores relating to both
episodic and working memory. No clear differences in effi-
cacy between the two active dose groups were seen. Perfor-
mance in the other cognitive tests did not differ significantly
between ORM-12741 and placebo.
The placebo group showed gradually increasing impair-
ment over the 12-week trial duration on memory composite
scores. This was not observed in the active-treated subjects,
whose performance was maintained at baseline levels. No
earlier published data are available on the progression of AD
asmeasured by CDR system composite scores in a patient pop-
ulation with moderate AD and NPS, such as that used in the
present trial. However, the Quality of Episodic Memory com-
posite score has previously been shown to decline significantly
Table 2
Estimated treatment differences of ORM-12741 versus placebo over 12 weeks of treatment
Variable Baseline mean (SD) Overall treatment effect
Estimated treatment difference versus
placebo (95% CI)
Quality of Episodic Memory
Placebo 82.7 (54.8) P 5 .030
Low dose 93.2 (67.0) 16.5 (0.28 to 32.63), P 5 .046
High dose 77.8 (59.0) 20.6 (4.57 to 36.7), P 5 .012
Quality of Working Memory
Placebo 1.07 (0.59) P 5 .193
Low dose 1.01 (0.68) 0.16 (20.02 to 0.33), P 5 .079
High dose 1.16 (0.48) 0.11 (20.06 to 0.28), P 5 .219
Quality of Memory
Placebo 185 (100) P 5 .013
Low dose 188 (111) 37.4 (10.9 to 63.9), P 5 .006
High dose 190 (88.3) 31.1 (5.19 to 57.1), P 5 .019
Speed of Memory
Placebo 9801 (7563) P 5 .654
Low dose 9928 (5595) 2147 (21267 to 973), P 5 .795
High dose 9940 (7170) 359 (2740 to 1457), P 5 .518
Power of Attention
Placebo 2199 (1049) P 5 .708
Low dose 2061 (736) 58.7 (2195 to 312), P 5 .646
High dose 2085 (1092) 248.7 (2303 to 205), P 5 .704
Continuity of Attention
Placebo 80.4 (18.4) P 5 .957
Low dose 82.4 (14.7) 20.38 (23.97 to 3.20), P 5 .833
High dose 84.7 (14.8) 20.52 (24.09 to 3.06), P 5 .775
Abbreviations: CI, confidence interval; SD, standard deviation.
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over 3 months in a placebo-treated population in a large thera-
peutic AD trial [26], AD patients with NPS have been shown to
progress faster than patients without NPS [27], and moderately
impaired AD patients decline more quickly than do mildly
impaired ones [28], consistent with the significant decline in
memory measures of the placebo-treated patients seen in the
present trial. The pattern of response in the active treatment
groups and the rate of decline in the placebo group closely
resemble those seen in some cholinesterase inhibitor registra-
tion trials [29] but differs from certain other trials where clear
initial improvement in cognitive performance have been seen
with symptomatic treatments [30,31]. This may be
speculated to be due to differences in study populations,
background treatments (particularly cholinesterase
inhibitors), and used efficacy measures.
Quality of Episodic Memory has been shown to be in
good agreement with the Alzheimer’s Disease Assessment
Scale–cognitive score (ADAS-Cog; r5 0.7) [32]. The effect
sizes of ADAS-Cog improvements with the three currently
approved cholinesterase inhibitors in their registration trials
have a median value of 0.28 at the higher used dose levels
[28], which is considerably smaller than the estimated effect
size for improvement seen in the present trial. This suggests
that the benefits seen with ORM-12741 in the present trial
are clinically meaningful.
Both ORM-12741 dose levels were clearly and statisti-
cally significantly superior to placebo in reducing NPI care-
giver distress scores during the 12-week treatment period.
However, no significant effect was seen in the NPI total
score, although numerically, NPI total scores also favored
the ORM-12741 low-dose group versus placebo.
The observed effects are consistent with predictions from
animal efficacy models where alpha-2C AR antagonists
have shown beneficial effects on learning and memory func-
tions, as well as antidepressant and antipsychotic properties
[7,8]. However, the present trial involved only a small
number of participants, and the duration of the study was
short. Due to the exploratory nature of this phase 2a trial,
the reported P-values were not corrected for multiple
comparisons. In addition, the decrease that was seen in the
memory measures was relatively large in the placebo group,
and no earlier results have been published using the same
outcome variables in a similar patient population. Therefore,
the efficacy results should be regarded as tentative, and
Fig. 3. NPI total and NPI caregiver distress scores. Data are presented as LS
means (SE) for changes from baseline. A negative change from baseline in-
dicates improvement. *P , .05, **P , .01 for difference versus placebo at
time point. Abbreviations: LS means, least squares means; NPI, Neuropsy-
chiatric Inventory; SE, standard error.
Table 3
Subjects experiencing adverse events
Adverse events Placebo (N 5 34) ORM-12741, 30–60 mg (N 5 33) ORM-12741, 100–200 mg (N 5 33)
Any AE 21 (61.8) 18 (54.5) 21 (63.3)
Any related AE 6 (17.6) 8 (24.2) 10 (30.3)
Any serious AE 0 0 1 (3.0)
Discontinuation due to an AE 0 1 (3.0) 2 (6.1)
Dose reduction due to an AE 3 (8.8) 2 (6.1) 3 (9.1)
AEs in 5 subjects overall
Headache 4 (11.8) 2 (6.1) 1 (3.0)
Urinary tract infection 3 (8.8) 1 (3.0) 5 (15.2)
Nausea 3 (8.8) 2 (6.1) 1 (3.0)
Vomiting 1 (2.9) 1 (3.0) 4 (12.1)
Diarrhea 2 (5.9) 2 (6.1) 1 (3.0)
Irritability 3 (8.8) 0 2 (6.1)
Abbreviation: AE, adverse event.
NOTE. Values are n (%).
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replication of the findings in larger populations will be
necessary for definitive conclusions on safety and efficacy.
ORM-12741 did not accumulate during the 12-week treat-
ment period. The measured trough concentrations of ORM-
12741 in the plasma of elderly subjects with AD were of
similar magnitude as previously observed at steady state after
similar dose levels in healthy volunteer subjects (Orion
Pharma, unpublished data). Based on this and the results of
the receptor occupancy study (Lovro et al., unpublished
data), it can be assumed that maximal alpha-2CAR occupancy
in the brain was reached by both dose levels after dosing. Over-
all, there was no clear separation between the two dose levels
of ORM-12741 regarding memory benefits or NPI scores,
although the low-dose group performed numerically slightly
better on some of the measures. When the alpha-2C AR PET
occupancy data are taken into account, it seems likely that
maximal effects were reached with both dose levels.
The safety profile in each treatment arm was considered
acceptable and no significant safety concerns were revealed.
The subjects in the high-dose group reported more treatment-
related AEs than the subjects in the low-dose and placebo
groups. However, the number of subjects with each specific
AEs was small, and no clear differences in the AE profiles
were seen between the treatments. One case of cholestasis
was reported as a serious adverse event in the high-dose group.
In conclusion, both investigated ORM-12741 doses
showed hints of superior efficacy compared to placebo in a
validated measure of episodic memory in subjects with
AD receiving standard cholinesterase inhibitor therapy in
this 12-week proof-of-concept trial. No differences in effi-
cacy were observed between the two investigated dose levels
of ORM-12741. This is the first clinical trial providing favor-
able safety data and hints of potential therapeutic benefit for
this novel mechanism of action in AD patients.
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RESEARCH IN CONTEXT
1. Systematic review: The authors searched PubMed for
the distribution and role of alpha-2C adrenoceptors in
the brain and the effects of selective alpha-2C adre-
noceptor antagonists in experimental animals. Rele-
vant research is cited. The literature suggests that
alpha-2C adrenoceptor antagonists improve cogni-
tion and have antipsychotic and antidepressant
properties. However, no previous clinical trials with
alpha-2C adrenoceptor antagonists have been re-
ported in patients with Alzheimer disease (AD).
2. Interpretation: This is the first clinical trial providing
evidence on an acceptable safety profile and hints of
potential therapeutic effects of an alpha-2C adreno-
ceptor antagonist in patients with AD.
3. Future directions: Replication of the findings in a
larger study population will be important. Efficacy
on both cognition and neuropsychiatric symptoms
should be further investigated.
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